Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China.

ABSTRACT:

Background

The use of adjunct rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations is supported by findings from large-scale clinical studies. This study is to investigate the efficacy and safety of adjunct rasagiline in Chinese patients with Parkinson's disease, as a product registration study.

Methods

This 16-week, randomized, double-blind, parallel-group, multicenter, placebo-controlled study of rasagiline 1 mg/day included levodopa-treated patients with Parkinson's disease and motor fluctuations. The primary efficacy endpoint was mean change from baseline in total daily OFF time over 16 weeks. Secondary endpoints were Clinical Global Impressions - Improvement (CGI-I), and change in Unified Parkinson's Disease Rating Scale (UPDRS) Activi

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC6026338 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature